The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)
At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy
Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.
A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:
- Get personalized resources that can help them navigate through the stages of their treatment.
- Access vetted information about their cancer & treatment from a health library.
- Receive surveys about their health and well-being.
- Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
- Connect with a physiotherapist to discuss healthy living and wellness.
Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.
At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Tulin Cil
- 電話番号:3984 416-946-4507
- メール:tulin.cil@uhn.ca
研究連絡先のバックアップ
- 名前:Emma Reel
- 電話番号:647-202-1028
- メール:emma.reel@uhn.ca
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G2M9
- University Health Network
-
コンタクト:
- Tulin Cil, MD, MEd
- 電話番号:4169464507
- メール:tulin.cil@uhn.ca
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Females (assigned female at birth)*
- Diagnosed with primary invasive BC and receiving curative intent treatment
- Must have neoadjuvant chemotherapy as their first step in treatment
- Receiving systemic therapy at UHN
- Age≥18
- Access to an electronic device with connection to the internet
- A valid email address
- Can communicate in English
Exclusion Criteria:
- Males (assigned male at birth), as BC surgical treatment options and experiences are different
- Diagnosed with non-operable breast cancer
- Stage 4/metastatic (whether determined at diagnosis or during surgery)
- Those with hearing or visual challenges
- Should not be enrolled in any other UHN study using an e-Health application
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:Control
Standard care |
|
|
実験的:Intervention (App)
App + standard care |
The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient Activation Measure 13 (PAM-13)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Impact of Events Scale - Revised (IES-R)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Generalized Anxiety Disorder 7 (GAD-7)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales). |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
時間枠:9 months post-baseline
|
A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information. |
9 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
時間枠:Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 42-item survey assessing quality of life specifically for breast cancer patients. The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Health Education Impact Questionnaire (heiQ)
時間枠:Baseline 9 months post-baseline
|
A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome. |
Baseline 9 months post-baseline
|
|
Clinical Evaluation Questionnaire -INS (CEQ-INS)
時間枠:9 months post-baseline
|
A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team. |
9 months post-baseline
|
|
Health Service Outcomes - Wait Times
時間枠:Until 15 months post-baseline
|
The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals. |
Until 15 months post-baseline
|
|
Health Service Outcomes - Ambulatory Clinical Activity
時間枠:Until 15 months post-baseline
|
Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS). |
Until 15 months post-baseline
|
|
Health Service Outcomes - Discharge Information
時間枠:Until 15 months post-baseline
|
Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery. |
Until 15 months post-baseline
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 24-5369
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。